Intas Rumored As Another Suitor For Biogen’s Biosimilars Business

Reports Of Interest From Accord Parent Company Follow Earlier Samsung Bioepis Rumor

 
• By Dave Wallace

Reports have named Intas as another possible buyer for Biogen’s biosimilars business, following earlier rumors that Samsung Bioepis could be interested in a deal. Generics Bulletin spoke to both Intas and Biogen for their reaction.

M&A written on red and blue blocks
Biogen has seen interest from multiple parties in its biosimilars business • Source: Shutterstock

More from Deals

More from Business